All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Corbus Pharmaceuticals Holdings Inc.’s lenabasum having failed its phase III test in diffuse cutaneous systemic sclerosis (SSc), attention turned to prospects with the cannabinoid receptor type 2 agonist for other indications.